Dr. Tempero on New Therapies for Pancreatic Cancer

Margaret A. Tempero, MD
Published Online: Monday, Jan 13, 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, gives an overview of new therapies for pancreatic cancer.

Pathways that are downstream of activated RAS, such as the MAPK and PI3K pathways, are potential targets for the treatment of pancreatic cancer.

Tempero says that stromal depleting agents are also in development. There is also an interest in optimizing vaccine strategies and changing the immune cell population in the microenvironment from a pro-tumor environment to an anti-tumor environment.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Lung Cancer Congress®Oct 06, 20162.0
Emerging Approaches for Patients With Less Common LymphomasOct 20, 20161.0
Publication Bottom Border
Border Publication